Johnson & Johnson (JNJ)

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66

Johnson & Johnson (NYSE:JNJ) reports upbeat earnings for Q1, with higher sales and raised fiscal 2026 guidance. Some analysts raise price targets.

Johnson & Johnson reports strong Q1, beating expectations and setting the stage for future growth. Analysts maintain Buy rating.

In a move that has sent shockwaves through the healthcare sector, Boston Scientific Corporation (NYSE: BSX) announced its definitive agreement to acquire Penumbra, Inc. (NYSE: PEN) for approximately $14.9 billion. The deal, priced at $374.00 per share, represents a significant premium for Penumbra shareholders and marks one of

Within 0.2% of its January all-time high. That's where the S&P 500 closed on Tuesday, not quite there yet, but close enough that the question investors are asking has quietly shifted from "when does this market stabilize?" to "when does it print a new record?"

In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of the much-feared "Stelara patent cliff." The healthcare titan announced adjusted earnings per share (EPS) of $2.70 on revenue of $24.1 billion, outpacing

Not all healthcare stocks are defensive in a downturn. Here's what to consider.

NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across the board. On April 14, 2026, the healthcare titan announced it was raising its full-year 2026 revenue and earnings guidance, signaling that

Johnson & Johnson (NASDAQ: JNJ) reported first-quarter financial results on Tuesday. The transcript from the company's first-quarter earnings call has been provided below.

As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue, in 2023, the New Brunswick-based giant has shed its "band-aid and baby powder" image to emerge as a high-octane, pure-play healthcare powerhouse. [...]

Johnson & Johnson Q1 pharma growth offsets immunology decline; company raises guidance and extends dividend streak.

Johnson & Johnson stock fell early Tuesday despite better-than-expected first-quarter sales and earnings, and a guidance hike.

Four of the 30 Dow Jones Industrial Average stocks report this week. Here's a look at the companies and what the key figures to watch are.

This Dividend King offers a rare mix of safety and upside heading into earnings.

Bristol Myers Squibb looks like a value buy, so long as its pipeline remains strong.

The future looks bright for this AI star.

The best time to buy stocks may be closer than you think -- and history has the receipts.

The choice is based on more than just the dividend payout.

Diversification is a winning strategy for the long term, especially in a volatile market.

This stock might help you sleep more easily at night.

These defensive consumer stocks are flashing buy signals while the market chases AI hype.

Moves made now could position your portfolio for success over time.

This Dividend King drug maker's dividend yield is roughly twice that of the S&P 500 index.